Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation

ABSTRACT: Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation

PROVIDER: PRJNA684760 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR13246567_1.fastq.gz	Fastqsanger.gz
	SRR13246567_2.fastq.gz	Fastqsanger.gz
	SRR13246568_1.fastq.gz	Fastqsanger.gz
	SRR13246568_2.fastq.gz	Fastqsanger.gz
	SRR13246569_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 66

Similar Datasets

Rewired m<sup>6</sup>A epitranscriptomic networks link mutant p53 to neoplastic transformation.

Project description:N6-methyladenosine (m6A), one of the most prevalent mRNA modifications in eukaryotes, plays a critical role in modulating both biological and pathological processes. However, it is unknown whether mutant p53 neomorphic oncogenic functions exploit dysregulation of m6A epitranscriptomic networks. Here, we investigate Li-Fraumeni syndrome (LFS)-associated neoplastic transformation driven by mutant p53 in iPSC-derived astrocytes, the cell-of-origin of gliomas. We find that mutant p53 but not wild-type (WT) p53 physically interacts with SVIL to recruit the H3K4me3 methyltransferase MLL1 to activate the expression of m6A reader YTHDF2, culminating in an oncogenic phenotype. Aberrant YTHDF2 upregulation markedly hampers expression of multiple m6A-marked tumor-suppressing transcripts, including CDKN2B and SPOCK2, and induces oncogenic reprogramming. Mutant p53 neoplastic behaviors are significantly impaired by genetic depletion of YTHDF2 or by pharmacological inhibition using MLL1 complex inhibitors. Our study reveals how mutant p53 hijacks epigenetic and epitranscriptomic machinery to initiate gliomagenesis and suggests potential treatment strategies for LFS gliomas.

| S-EPMC10042811 | biostudies-literature

Rewired m6A epitranscriptomic networks link mutant p53 to neoplastic transformation

Project description:We report the application for high-throughput profiling of transcriptome, chromatin-associated proteins and histone-modifications on a genome-wide level in iPSC-derived family control astrocytes vs LFS (Li-Fraumeni Syndrome) patient astrocytes.

2023-02-18 | GSE163088 | GEO

Susceptibility of neoplastic transformation of human dental pulp stem cells DPSC in hypoxia

Project description:Neoplastic transformation of DPSC cultured under Hypoxia versus normoxia. Molecular characterization of cell markers associated with tumorigenicity.

2013-07-01 | GSE22673 | GEO

Susceptibility of neoplastic transformation of human dental pulp stem cells DPSC in hypoxia

Project description:Neoplastic transformation of DPSC cultured under Hypoxia versus normoxia. Molecular characterization of cell markers associated with tumorigenicity. DPSC array CGH profiles of experimental (HX48h and HX72h) and reference (NX48 and NX72h) genomic DNA samples

2013-07-01 | E-GEOD-22673 | biostudies-arrayexpress

Targeted Profiling of Epitranscriptomic Reader, Writer and Eraser Proteins in Radioresistant Breast Cancer Cells

Project description:Epitransciptomic reader, writer and eraser (RWE) proteins recognize, install, and remove modified nucleosides in RNA, which are known to play essential roles in RNA processing, splicing, and stability. Here, we established a liquid chromatography–parallel reaction monitoring (LC-PRM) method for high-throughput profiling of a total of 152 epitransciptomic RWE proteins, including 68 human epitranscriptomic RWE proteins deposited in the Modomics database. To our knowledge, this is the first report of quantifying a comprehensive list of epitranscriptomic RWE proteins using LC-PRM. To access the roles of epitranscriptomic RWE proteins in breast cancer radioresistance, we applied the LC-PRM method, in conjunction with stable isotope labelling by amino acids in cell culture (SILAC), to quantify these proteins in two pairs of matched parental/radioresistant breast cancer cells (i.e., MDA-MB-231 and MCF-7 cells, and their radioresistant counterparts, i.e., C5 and C6 cells). We found that eight epitranscriptomic RWE proteins were commonly altered by over 1.5-fold in the two pairs of matched breast cancer cells, from which TRMT1 (an m2,2G writer) may play a role in promoting breast cancer radioresistance due to its clinical relevance and correlation with DNA repair gene sets. Furthermore, we envision that the LC-PRM method is applicable for studying the roles of epitranscriptomic RWE proteins in the metastatic transformation of cancer and therapeutic resistance of other types of cancer.

2022-08-15 | PXD030387 | Pride

Targeted Quantitative Profiling of Epitranscriptomic Reader, Writer and Eraser Proteins in Colorectal Cancer Metastasis

Project description:Epitranscriptomic reader, writer and eraser (RWE) proteins are involved in the recognition, installation, and removal, respectively, of chemical modifications in RNA, and aberrant expressions of some of these proteins were found to be associated with cancer initiation and progression. Here, we our recently established parallel-reaction monitoring (PRM)-based targeted proteomic method, in conjunction with stable isotope labelling by amino acids in cell culture (SILAC), to investigate the differential expression of epitranscriptomic RWE proteins in a matched pair of primary/metastatic colorectal cancer (CRC) cells (i.e., SW480/SW620) derived from the same patient. We were able to detect 113 non-redundant epitranscriptomic RWE proteins in these two lines of cells. We found that 48 and 5 proteins were respectively up- and down-regulated by at least 1.5-fold in SW620 over SW480 cells. Particularly, NAT10, HNRNPC, and DKC1 were markedly up-regulated, and their potential roles in driving CRC metastasis were supported by recent studies. Interrogation of the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data revealed that the elevated expressions of these and other RWE proteins are also accompanied with CRC initiation, suggesting the roles of these proteins in both the initiation and metastatic transformation of CRC. It can be envisaged that the established PRM method can be further utilized to examine the roles of epitranscriptomic RWE proteins in the metastatic transformations of other types of cancer.

2022-08-15 | PXD030907 | Pride

CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation

Project description:CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation

| PRJNA849512 | ENA

Competition and community succession link N transformation and greenhouse gas emissions in urine patches

Project description:Competition and community succession link N transformation and greenhouse gas emissions in urine patches

| PRJNA593862 | ENA

CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation [Methyl-seq]

Project description:CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation [Methyl-seq]

| PRJNA849520 | ENA

CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation [RNA-seq]

Project description:CDDO drives transcriptomic and epigenetic reprogramming in response to TPA-induced JB6 cell neoplastic transformation [RNA-seq]

| PRJNA849521 | ENA

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data